LRRK2
LRRK2 inhibitors are compounds that target and inhibit the activity of Leucine-Rich Repeat Kinase 2 (LRRK2), an enzyme involved in several cellular processes, including autophagy, vesicle trafficking, and inflammation. Mutations in the LRRK2 gene are associated with an increased risk of developing Parkinson's disease, making LRRK2 a significant target for neurodegenerative disease research. Inhibitors of LRRK2 are crucial for exploring its role in Parkinson's disease and for developing potential therapeutic strategies. At CymitQuimica, we offer a selection of LRRK2 inhibitors to support your research in neurodegeneration, kinase signaling, and therapeutic development.
Found 48 products for "LRRK2".
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
BIX 02565
CAS:BIX 02565 is a potent inhibitor of ribosomal S6 kinase 2 (RSK2, IC50: 1.1 nM).Formula:C26H30N6O2Purity:97.44% - 99.7%Color and Shape:SolidMolecular weight:458.5554MLi-2
CAS:MLi-2: Novel, potent CNS-active LRRK2 inhibitor; IC50s: 0.76nM in vitro, 1.4nM cellular, 3.4nM binding.Formula:C21H25N5O2Purity:98.96% - 99.07%Color and Shape:SolidMolecular weight:379.4555RN277
RN277 is an inhibitor of LRRK2 type II kinase (LRRK2type II kinase). It serves as a cellular tool targeting the inactive state of LRRK2. In vitro, RN277 inhibits LRRK1 kinase activity and the kinase activity of LRRK2, with an IC50 of 70 nM. Additionally, it reduces Rab8a phosphorylation in a dose-dependent manner. RN277 is useful for Parkinson's disease research.Color and Shape:Odour SolidPROTAC LRRK2 Degrader-3
CAS:PROTACLRRK2 Degrader-3 is a PROTACLRRK2 degrader with a DC50 of 0.17 nM. This compound can be utilized in research related to Parkinson's disease and inflammation.Formula:C44H54N10O5Molecular weight:802.98PROTAC LRRK2 Degrader-5
CAS:PROTAC LRRK2 Degrader-5 Formula (V) is an LRRK2 PROTAC degrader. It can be utilized in the research of diseases associated with LRRK2, such as Parkinson's disease (PD).Formula:C46H57FN10O4Molecular weight:833.01XL01126
CAS:XL01126 LRRK2 degrader (DC50 14 nM G2019S, 32 nM WT) BBB-penetrant probe for Parkinson’s disease and LRRK2 signaling and protein degradation studies.Formula:C50H64ClFN10O6S2Purity:99.98%Color and Shape:SolidMolecular weight:1019.69CZC-54252 hydrochloride
CAS:CZC-54252 hydrochloride: selective LRRK2 inhibitor; IC50 = 1.85/1.28 nM (wild-type/G2019S); neuroprotective; EC50 = 1 nM for G2019S injury.Formula:C22H26Cl2N6O4SPurity:99.28%Color and Shape:SolidMolecular weight:541.45RN341
RN341 is a LRRK2-specific type II kinase inhibitor (IC50 of 296 nM). It prevents the phosphorylation of LRRK2 by stabilizing an open conformation, thereby avoiding S935 dephosphorylation. Additionally, RN341 rescues LRRK2-mediated kinesin motility blockage by preventing microtubule binding. This compound effectively inhibits both wild-type and G2019S LRRK2 at the cellular level, offering a novel avenue for Parkinson's disease research.Color and Shape:Odour SolidEB-42486
CAS:EB-42486 is an effective and highly selective inhibitor of G2019S-LRRK2 with an IC50 < 0.2 nM.Formula:C22H22N8OPurity:99.53%Color and Shape:White SolidMolecular weight:414.4631PROTAC LRRK2 Degrader-4
CAS:PROTACLRRK2 Degrader-4 is a PROTACLRRK2 degrader with a DC50 of 0.79 nM, employed in research related to Parkinson's disease and inflammation.Formula:C45H56N10O5Molecular weight:817.01FX 2149
CAS:FX 2149 is a GTP-binding inhibitor that potently inhibits LRRK2 GTP binding and kinase activity in vitro and attenuates the toxic effects of LRRK2 in Parkinson’s disease models.Formula:C15H17N3O3SPurity:99.94%Molecular weight:319.38Nictide
CAS:Nictide, a peptide substrate for LRRK2 (leucine-rich repeat protein kinase-2), undergoes phosphorylation by the activated form of LRRK2[G2019S], exhibiting a Km value of 10 μM.Formula:C123H193N45O28Color and Shape:SolidMolecular weight:2750.13JH-XII-03-02
CAS:JH-XII-03-02 is a potent and selective leucine-rich repeat kinase 2 (LRRK2) proteolysis targeting chimera (PROTAC) degrader, utilized in Parkinson's Disease (PDFormula:C43H51N9O10Purity:98%Color and Shape:SolidMolecular weight:853.92PROTAC LRRK2 Degrader-2
CAS:PROTAC LRRK2 Degrader-2 is a PROTAC-based degrader targeting LRRK2 with a DC50 of 0.14 nM. It recruits LRRK2 or its mutants to cereblon E3 ubiquitin ligase, facilitating the targeted ubiquitination and subsequent proteasomal degradation of LRRK2. PROTAC LRRK2 Degrader-2 is applicable in Parkinson's disease research.Formula:C43H53N11O5Molecular weight:803.95PROTAC LRRK2 Degrader-1
CAS:PROTAC LRRK2 Degrader-1 (compound 18) is a PROTAC degrader targeting leucine-rich repeat kinase 2 (LRRK2) with an IC50 of less than 10 nM. It is applicable for research in Parkinson's disease.Formula:C45H54FN9O5Molecular weight:819.97CC-3240
CAS:CC-3240 (compound 13), a molecular glue degrader of CaMKK2 based on CC-8977, has an IC50 of 9 nM [1].Formula:C52H64N6O7SColor and Shape:SolidMolecular weight:917.17Anti-LRRK2 Antibody (1C773)
Anti-LRRK2 Antibody (1C773) is an antibody targeting LRRK2. Anti-LRRK2 Antibody (1C773) can be used in ELISA, IHC.Color and Shape:Odour LiquidGNE-7915 tosylate
CAS:GNE-7915 tosylate is a potent, selective, and brain-penetrant LRRK2 inhibitor, boasting an IC50 value of 9 nM.Formula:C26H29F4N5O6SColor and Shape:SolidMolecular weight:615.597HG-10-102-01
CAS:HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 of 20.3 nM).Formula:C17H20ClN5O3Purity:99.59%Color and Shape:SolidMolecular weight:377.825LRRK2-IN-1
CAS:LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.Formula:C31H38N8O3Purity:98% - 98.82%Color and Shape:SolidMolecular weight:570.69
